Biogen: The $300B Drug Opportunity You're Missing

Описание: BIIB (Biogen) stock surged 4% - the real story is $300B in new drug revenue.
Is Biogen stock a buy in 2026? The market is blind to Leqembi's blockbuster potential.

While Biogen's immediate earnings beat grabbed headlines, InvestIq uncovers the massive, underappreciated long-term revenue stream from its newer drugs. Leqembi, in particular, could re-rate BIIB stock significantly beyond current analyst expectations, creating a multi-billion dollar opportunity.

We dive deep into the financials and the science to show why this isn't just about a quarterly report, but a fundamental shift in Biogen's future valuation.

#InvestIq #BIIB #AIStocks #StockMarket #Investing

---
This video uses AI-assisted production (synthetic voice). Analysis and editorial direction are human-reviewed. Educational content only — not financial advice.